Cargando…
The failure of DAC to induce OCT2 expression and its remission by hemoglobin-based nanocarriers under hypoxia in renal cell carcinoma
Background: Human organic cation transporter 2 (OCT2) is the most abundant and important uptake transporter involved in the renal excretion of cationic drugs. Abnormal hypermethylation- mediated silencing of OCT2 results in oxaliplatin resistance in renal cell carcinoma (RCC). The epigenetic activat...
Autores principales: | Chen, Lu, Wang, Zeyang, Xu, Qingwen, Liu, Yuxi, Chen, Le, Guo, Suhang, Wang, Hua, Zeng, Kui, Liu, Junqing, Zeng, Su, Yu, Lushan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7069078/ https://www.ncbi.nlm.nih.gov/pubmed/32206108 http://dx.doi.org/10.7150/thno.39944 |
Ejemplares similares
-
Blockade LAT1 Mediates Methionine Metabolism to Overcome Oxaliplatin Resistance under Hypoxia in Renal Cell Carcinoma
por: Xu, Qingwen, et al.
Publicado: (2022) -
Hypoxia-activated prodrugs and redox-responsive nanocarriers
por: Zeng, Yun, et al.
Publicado: (2018) -
The DAC guidelines. guidance for development co-operation /
Publicado: (2001) -
Upregulation of miR-489-3p and miR-630 inhibits oxaliplatin uptake in renal cell carcinoma by targeting OCT2
por: Chen, Lu, et al.
Publicado: (2019) -
The DAC system and associations with multiple myeloma
por: Ocio, Enrique M., et al.
Publicado: (2010)